Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration

Details for Australian Patent Application No. 2004257772 (hide)

Owner Duramed Pharmaceuticals, Inc.

Inventors Bronnenkant, Lance, J.; Iskold, Beata; Reape, Kathleen, Z.; Benn-Maimon, Carole, S.; Hait, Howard; Bell, Robert, G

Agent Davies Collison Cave

Pub. Number AU-B-2004257772

PCT Pub. Number WO2005/007112

Priority 60/487,257 16.07.03 US

Filing date 16 July 2004

Wipo publication date 27 January 2005

Acceptance publication date 17 December 2009

International Classifications

A61K 31/56 (2006.01) - Compounds containing cyclopenta[a]hydrophenanthrene ring systems

A61K 31/565 (2006.01) - not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol

A61K 31/57 (2006.01) - substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone

Event Publications

23 February 2006 PCT application entered the National Phase

  PCT publication WO2005/007112 Priority application(s): WO2005/007112

17 December 2009 Application Accepted

  Published as AU-B-2004257772

15 April 2010 Standard Patent Sealed

19 August 2010 Alteration of Name

  The name of the patentee has been altered to Teva Women's Health, Inc. Amendments

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004257777-Method of treating diabetes type II

2004257770-Device to assist hyperhydrosis therapy